术后复发风险中危的分化型甲状腺癌患者^(131)I治疗与否对预后的影响  

Effect of using ^(131)I therapy or not after thyroidectomy in patients with intermediate-risk differentiated thyroid cancer

作　　者：齐志兵 田甜[1] 黄蕤[1] Qi Zhibing;Tian Tian;Huang Rui(Department of Nuclear Medicine,West China Hospital of Sichuan University,Chengdu 610041,China;Department of Nuclear Medicine,Jiujiang First People′s Hospital,Jiujiang 332000,China)

机构地区：[1]四川大学华西医院核医学科,成都610041 [2]九江市第一人民医院核医学科,九江332000

出　　处：《中华核医学与分子影像杂志》2023年第6期382-384,共3页Chinese Journal of Nuclear Medicine and Molecular Imaging

摘　　要：复发风险中危的分化型甲状腺癌(DTC)患者术后行^(131)I治疗的主要目的是清除隐匿性病灶、减少DTC复发和转移、提高患者的无病生存率,这被称为辅助治疗,同时也兼具了清除残留甲状腺组织(简称清甲)的作用。2015年美国甲状腺协会(ATA)治疗指南建议复发风险中危的DTC患者选择性考虑行^(131)I治疗。该文对行与未行^(131)I治疗的复发风险中危DTC患者的相关文献进行综述,发现^(131)I对改善该类患者复发和生存的结论并不一致。中危患者除术后不明原因的高甲状腺球蛋白(Tg)血症外,尚无其他统一的临床病理特征可用于推荐行^(131)I治疗。The main goal of radioactive iodine(RAI)administrated for patients with indeterminate-risk differentiated thyroid cancer(DTC)is removing occult microscopic residual disease after a total thyroidectomy,aiming to reduce recurrence and metastasis,then to improve disease-free survival.This treatment is called as adjuvant therapy,which also ablates the remnant thyroid tissue together.According to the current thyroid cancer management guidelines(2015 American Thyroid Association management guidelines),intermediate-risk patients can be selectively administered RAI.By reviewing articles about DTC patients with indeterminate-risk who underwent RAI or not after thyroidectomy,this article shows that there are inconsistent opinions on ^(131)I decreasing recurrence and improving survival.In addition,apart from unexplained hyperthyroglobulinemia as an indication for ^(131)I therapy,no other uniform clinicalpathological characteristics are recommended.

关 键 词：甲状腺肿瘤 复发 放射疗法 碘放射性同位素 预后 

分 类 号：R736.1[医药卫生—肿瘤]